Chromium Treatment Has No Effect in Patients With Type 2 Diabetes in a Western Population
Open Access
- 1 May 2007
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (5) , 1092-1096
Abstract
OBJECTIVE—Chromium treatment has been reported to improve glycemic control in patients with type 2 diabetes. However, concern exists about the possible toxic effects of chromium picolinate. The aim of this study was to determine the effect of chromium treatment in the form of chromium yeast on glycemic control in a Western population of patients with type 2 diabetes who were being treated with oral hypoglycemic agents.Keywords
This publication has 29 references indexed in Scilit:
- Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 DiabetesDiabetes Care, 2006
- Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitusJournal of Trace Elements in Medicine and Biology, 2004
- Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705ITBlood Pressure Monitoring, 2003
- Ultrastructural damage in chromium picolinate-treated cells: a TEM studyJBIC Journal of Biological Inorganic Chemistry, 2002
- The validity of predicted body fat percentage from body mass index and from impedance in samples of five European populationsEuropean Journal of Clinical Nutrition, 2001
- Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetesDiabetes, 1997
- Chromium Oligopeptide Activates Insulin Receptor Tyrosine Kinase ActivityBiochemistry, 1997
- Patient noncompliance with self-administered chemotherapyCancer, 1990
- Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjectsDiabetes, 1980
- Diabetes and cardiovascular disease. The Framingham studyJAMA, 1979